Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tesis Biosciences

Request full access

Tesis Biosciences’ unique integrated medical platform is revolutionizing targeted genetic sequencing

Phoenix, United StatesHealth

About Tesis Biosciences

Tesis Biosciences, established in 2019, operates in the healthcare sector, specializing in targeted genetic sequencing and high-complexity laboratory testing. The company was founded by Ronald King and Divyen Patel. The firm, originally known as Tesis Labs, rebranded in November 2021 to Tesis Biosciences to reflect its expanded focus beyond laboratory services to include advancing clinical research and diagnostics. A significant milestone was the acquisition of Genome Explorations in February 2022, which accelerated its capabilities in clinical research for chronic diseases.

The company's core business revolves around a genetically integrated medical platform used for advanced testing to address major chronic conditions like heart disease, cancer, diabetes, and Alzheimer's. Tesis Biosciences serves a diverse client base that includes physicians, hospitals, pharmaceutical companies, medical device companies, and accountable care organizations (ACOs). Its business model involves forming collaborative partnerships to provide these entities with the necessary tools and data for diagnostics, clinical trials, and personalized patient care. Revenue is generated by offering genetic testing services, providing access to its comprehensive genetic database to de-risk drug development, and supplying data and bioinformatics analysis to help partners design protocols for earlier diagnosis.

The primary service is providing customizable, high-complexity genetic testing panels. These panels are designed to identify changes in chromosomes, genes, or proteins, which helps in predicting specific chronic diseases. For pharmaceutical and medical device partners, Tesis offers access to its genetic data repository to accelerate product development and approval processes. For healthcare providers such as hospitals and physician groups, the company delivers testing expertise and technology that enables the creation of personalized care plans based on a patient's genetic profile. This is facilitated through a user-friendly interface and portals that provide 24/7 access to real-time results. The company also provides services for pharmacogenomics, which helps in determining a patient's response to a wide range of pharmaceuticals.

Source: Dealroom company data

At a glance

Headquarters
Phoenix, United States
Sector
Health

Tesis Biosciences in the Phoenix ecosystem

Live from Dealroom

The Tesis Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • KG Investments
  • Xcellerant Ventures
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tesis Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tesis Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.